据《南方都市报》报道，因"拒绝将AI引入其所在医院的电子病历系统"的发言，近日，国家传染病医学 中心主任张文宏引发热议。张文宏表示，若将AI引入病历系统，会改变现有的年轻医生培养体系。 不难预见，如果AI介入了诸如病历书写这样的基础工作，医生在一般性工作中的锻炼和经验积累的机 会会减少，但这在某种程度上其实是不可避免的。 因为在科技的推动下，人类的很多能力都在不断退化。正如前文提到的，现在的法医都在用AI识别指 纹，个人识别指纹的能力在下降。可以想象，如果AI可以轻松识别肺里的小结节，那么医生在这方面 的能力也会下降。 不只是医学，在方方面面我们都面临着"AI让人的能力退化"的情况。例如，随着技术的进步，不少司机 在识别道路的能力方面，就在逐步退步。而且，如果关闭倒车影像，当下的不少司机甚至不敢倒车，而 这在过去可是汽车司机的必备技能。 不过，张文宏并不是全盘拒绝AI。他表示，自己也会使用AI，他接触的病人量太大、太复杂，短期内 处理大量病人时，一般会让AI"先看一遍"，"但是我一般看一眼就知道（AI）哪里是错的"，而年轻医生 则有可能被误导。他强调，是否会被误导，取决于"你的能力是不是强过这个AI"。 AI ...

Core Insights - The Chinese government has officially launched the "Artificial Intelligence +" initiative, focusing on enhancing the healthcare sector through AI applications, aiming to improve the quality of life and healthcare services [2] - The healthcare industry is becoming a primary area for AI technology implementation, transitioning from optional to essential applications, with significant growth expected in the AI healthcare market [2][3] Industry Overview - The healthcare sector faces critical challenges such as uneven resource distribution, high physician workloads, and low research translation efficiency, creating ample opportunities for AI applications [3] - By 2025, the global AI application market is projected to reach $127 billion, with the healthcare sector accounting for 20% of this total [2] - The "AI + healthcare" market is expected to grow at a compound annual growth rate of over 29%, reaching $70 billion by 2032 [2] AI Applications in Healthcare - AI applications in healthcare have evolved through various stages, with clinical decision support systems (CDSS) being a key area of focus, addressing the knowledge gap between medical advancements and physician expertise [3][4] - The introduction of large language models has significantly improved the capabilities of CDSS, allowing for real-time updates and broader disease coverage, with accuracy rates surpassing 91% in some cases [5][11] - Medical imaging AI has matured, transitioning from basic disease screening to advanced multi-modal analysis, enhancing diagnostic precision and patient outcomes [6][7] Business Models and Commercialization - The commercialization of medical imaging AI is shifting from product sales to service-based models, driven by the integration of AI into healthcare workflows [7][10] - Companies like Ping An are leveraging AI to enhance patient services, streamline processes, and improve healthcare accessibility, with AI assisting in over 50% of family doctor tasks [8][11] - The AI healthcare market is facing challenges related to high development costs, long return on investment periods, and difficulties in monetization due to varying payment capabilities across healthcare institutions [21][22] Challenges and Future Outlook - Despite advancements, the integration of AI in healthcare faces hurdles such as data quality, regulatory issues, and the need for explainability in AI decision-making [16][19] - The lack of standardized, high-quality data across healthcare institutions hampers the training of AI models, necessitating improvements in data governance and sharing mechanisms [18][19] - The AI + healthcare sector is expected to enter a new phase of large-scale implementation by 2026, driven by collaborative efforts and continuous technological innovation [22]

资金流向方面，今日该股主力资金净流入2387.01万元，其中，特大单净流入2.52亿元，大单资金净流出 2.28亿元。近5日主力资金净流入2.64亿元。 融资融券数据显示，该股最新（1月15日）两融余额为19.01亿元，其中，融资余额为18.83亿元，融券余 额为1757.66万元。近5日融资余额合计增加6.92亿元，增幅为58.11%，融券余额合计增加682.92万元， 增幅63.54%。（数据宝） 美年健康1月16日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 广发证券股份有限公司深圳后海证券营业部 | 45344.41 | 38.39 | | 买二 | 国泰海通证券股份有限公司上海分公司 | 38808.10 | 0.92 | | 买三 | 深股通专用 | 36113.50 | 34744.54 | | 买四 | 国泰海通证券股份有限公司上海浦东新区海阳西路证券营 业部 | 25367.53 | 1804.90 | | 买五 | 国联民生证券股份有限公司宁波分公司 ...

证券之星消息，1月16日医疗服务板块较上一交易日下跌2.51%，迪安诊断领跌。当日上证指数报收于 4101.91，下跌0.26%。深证成指报收于14281.08，下跌0.18%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | --- | --- | --- | --- | --- | --- | --- | | 301509 | 金凯生松 | 38.43 | 2.15% | | 5.17万 | 1.96亿 | | 301096 | 百诚医药 | 59.40 | 1.50% | | 3.12万 | 1.84亿 | | 600721 | 自花医药 | 9.84 | 0.92% | | 28.61万 | 2.79亿 | | 002821 | 凯莱英 | 107.33 | 0.78% | | 5.97万 | 6.39亿 | | 603259 | 药明康德 | 104.30 | 0.71% | | 44.78万 | 46.80亿 | | 688621 | 阳光诺和 | 75.88 | 0.44% | | 2.41万 | 1.82亿 | | 688 ...

润达医疗（603108）(603108.SH)发布公告，经公司财务部门初步核算，预计2025年年度归属于上市公 司股东的净利润为负值，公司2025年年度经营业绩将出现亏损。 ...

智通财经APP讯，润达医疗(603108.SH)发布公告，经公司财务部门初步核算，预计2025年年度归属于 上市公司股东的净利润为负值，公司2025年年度经营业绩将出现亏损。 ...

Group 1 - The core viewpoint of the news is that Langma Information (300288) has experienced a significant decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business operations [2] - As of January 16, 2026, Langma Information's stock closed at 15.0 yuan, down 3.97%, with a turnover rate of 6.91% and a trading volume of 177,300 hands, resulting in a transaction amount of 267 million yuan [1] - The net outflow of main funds on January 16 was 14.82 million yuan, accounting for 5.55% of the total transaction amount, while retail investors saw a net inflow of 9.07 million yuan, representing 3.4% of the total transaction amount [1] Group 2 - For the first three quarters of 2025, Langma Information reported a main operating income of 224 million yuan, a year-on-year decrease of 24.75%, and a net profit attributable to shareholders of 13.51 million yuan, down 67.04% year-on-year [2] - In Q3 2025, the company recorded a single-quarter main operating income of 72.53 million yuan, a decline of 36.46% year-on-year, and a net profit attributable to shareholders of -0.93 million yuan, reflecting a year-on-year decrease of 105.48% [2] - The company's debt ratio stands at 17.27%, with investment income of 16.99 million yuan and financial expenses of -2.53 million yuan, while the gross profit margin is reported at 29.25% [2]

21智讯1月16日电，润达医疗发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为负 值，公司2025年年度经营业绩将出现亏损。原因：经上海润达医疗科技股份有限公司（以下简称"公 司"）财务部门初步核算，预计2025年年度归属于上市公司股东的净利润为负值，公司2025年年度经营 业绩将出现亏损。公司将严格遵循《上海证券交易所股票上市规则》等相关规定，加快推进财务核算工 作，尽快披露2025年年度业绩预告。最终财务数据请以公司正式披露的2025年年度报告为准。 ...

Investment Rating - The report indicates a positive outlook for the AI+Pharma and AI+Healthcare sectors, suggesting a shift towards data and algorithm-driven drug development and clinical applications [3][6]. Core Insights - The collaboration between NVIDIA and Eli Lilly to establish the first AI+Pharma joint innovation lab signifies a major step in integrating AI into drug R&D, with a planned investment of up to 1 billion USD over five years [3][6]. - Tempus AI's preliminary revenue for 2025 reached approximately 1.27 billion USD, reflecting an 83% year-over-year growth, validating the commercial viability of AI in clinical testing and medical data [3][6]. - The industry is currently experiencing a phase characterized by technological breakthroughs, active funding, and accelerated application of AI in pharmaceuticals and healthcare [3][6]. Summary by Sections AI+Pharma - The establishment of the AI+Pharma lab aims to address key challenges in drug development, combining expertise from both NVIDIA and Eli Lilly [3][6]. - The partnership is expected to elevate AI's role from a mere tool to a core productivity driver in drug R&D, transitioning the industry from experience-driven to data-driven methodologies [3][6]. AI+Healthcare - Tempus AI reported a diagnostic revenue of approximately 955 million USD, up 111% year-over-year, driven by significant growth in oncology and genetic testing [3][6]. - The data and application segment generated about 316 million USD, marking a 31% increase, with data licensing (Insights) growing by 38% [3][6]. Industry Trends - The report highlights a favorable environment for AI in pharmaceuticals, supported by technological advancements, policy backing, and a vibrant investment landscape [3][6]. - The launch of OpenAI's ChatGPT Health and the significant user engagement indicate a growing interest and application of AI technologies in healthcare [3][6]. - Relevant investment targets in AI drug discovery and healthcare applications include companies like XtalPi, Insilico Medicine, and Meinian Onehealth [3][6].

智通财经APP获悉，康龙化成(03759)续跌超3%，截至发稿，跌3.44%，报23.04港元，成交额1.57亿港 元。 公司预期配售所得款项总额及净额将分别为约13.34亿港元及13.19亿港元，当中约70%将用于项目建 设，以加强实验室服务设施、药物工艺开发及生产设施的能力及产能；约10%将用于偿还银行贷款及其 他借款，以优化资本结构；余下约20%将用于补充营运资金及作其他一般用途。 消息面上，康龙化成昨日发布公告称，拟配售近5844.08万股新H股，占公司经扩大后已发行股份总数约 3.19%及已发行H股总数约16.57%，配售价每股22.82港元，较1月14日股份收市价折让约8.5%。 ...